TKO Group, the sports and entertainment company that comprises WWE and UFC, presents a striking financial profile with growth potential, analysts at the Bank of America believe.
The bank's analysts have initiated coverage on the company with a ‘Buy’ rating and a $100 price target, implying a 25% upside to TKO's share price of $80 on Friday morning.
In stark contrast to the constant rain, the UK pub and restaurant sector had a dry start to the year with middling like-for-like (LFL) sales growth amidst challenging weather conditions and sustained cost pressures.
That is Stifel’s read of the market, with the bank pointing to February’s LFL sales edging just 1.4% higher.
ASOS PLC (LSE:ASC) and Boohoo Group PLC (AIM:BOO) are both facing downside on the back of ever-increasing competition in the UK’s online fashion sector, analysts have said.
Coupled with a resurgence in high street shopping and ongoing cost of living pressures, each face tough outlooks, Shore Capital analysts said in a note on Friday.
discoverIE Group plc’s current share price softness offers a “good entry point” for the OEM components manufacturer, reckon Liberium analysts.
Liberum maintained a ‘buy’' rating on discoverIE stock with a 980p price target, noting that the London-listed group is “on track to meet FY24 underlying earnings expectations”.
Rolls-Royce Holdings PLC (LSE:RR.), easyJet PLC and Tesco PLC (LSE:TSCO) have received backing from UBS analysts in the bank’s list of top stock picks for 2024.
Following a stellar year of gains last year as new chief executive Tufan Erginbilgic implemented a turnaround plan, UBS suggested investors could expect even more positivity ahead from aircraft engine maker Rolls-Royce.
Fathom Nickel Inc (CSE:FNI, OTCQB:FNICF) has earned an initial ‘Buy’ rating from analysts at Couloir Capital who are impressed with the company’s progress in exploring for nickel at its Saskatchewan projects.
In a note to clients, the analysts highlighted that Fathom Nickel’s projects, the Albert Lake and Gochanger Lake projects, are located within an underexplored portion of the Trans-Hudson Corridor that hosts nickel-producing mines like Thompson and Raglan.
CVS Group (AIM:CVSG), the veterinary service provider, has been downgraded to "sector perform" by analysts at RBC following the CMA's review of the industry.
The group's price target has also been reduced from 2,100p to 1,200p, with the new price representing around a 15% premium to its current market value.
UBS has upgraded Admiral Group plc shares to 'buy' from 'neutral' on valuation grounds.
It points out that the stock in the general insurer is currently trading at a near-five-year low, yet the fundamentals look rock solid.
Shore Capital has reaffirmed its 'buy' recommendation on shares in ITV PLC (LSE:ITV), setting a target price of 116p per share, which represents an approximate 61% upside from the current stock valuation.
This endorsement follows the media giant's announcement of its full-year results, which, despite a challenging backdrop, demonstrated strong strategic execution and robust performance across its operations.
Shore Capital has downgraded shares of Intertek Group PLC (LSE:ITRK) to 'sell' from 'hold' with the broker citing the 'full' valuation of the stock while acknowledging the fundamental importance and growing demand for its testing services.
The downgrade follows the release of Intertek's full-year results, which Shore described as 'exceptional'. The company's operating margin was reported at 16.6%, slightly above expectations and marking an increase from the previous year.
Shares in Trident Royalties PLC (AIM:TRR, OTCQX:TDTRF) were up 2% in morning trading after it updated on a mining project that has the potential to move the dial financially for the group.
It relates to Lithium Americas' award of a US Department of Energy (DoE) loan for $2.26 billion under the Advanced Technology Vehicles Manufacturing (ATVM) Loan Program.
Faron Pharmaceuticals Limited (AIM:FARN) will release updated results from its BEXMAB clinical study of its drug bexmarilimab next Tuesday (Mar 19) with analysts and investors keenly eyeing disease progression data from patients with myelodysplastic syndromes (MDS), a type of blood cancer.
Panmure Gordon in a research note pointed out the median survival rate for people with the refractory form of the disease is four to six months.
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) has "transformational resource potential" on its hands with the Itumbala West-1 drilling campaign, according to Liberum analysts.
Liberum stated that Helium One’s current share price “does not fully reflect the commercial potential of Itumbula in particular”, with analysts highlighting high concentrations (4.7%) of helium as a potential "world-class" discovery.
AstraZeneca PLC (LSE:AZN)’s £780 million takeover of France-based Amolyt Pharma on Thursday failed to tempt much of a reaction from Deutsche Bank analysts.
According to the bank, the acquisition “is sufficiently modest to pass under the radar without any visible impact on leverage or profit and losses”.